What it does
More about the company
Who it is
Novo makes medicines that copy gut hormones. Semaglutide imitates GLP-1, a hormone that lowers blood sugar and appetite; a weekly shot or a daily pill helps people lose a sixth of their weight. Ozempic, Wegovy and the pill Rybelsus were about three quarters of its DKK 309B of 2025 sales.
Insurers and governments pay for it instead of leaving obesity untreated or turning to surgery. CagriSema, which adds a second hormone, is the next drug: in trials it beat a low dose of Lilly's rival but not its top dose.
How it makes money
Novo sells each prescription through wholesalers, insurers and governments, and keeps about 78 cents of every sales dollar after making the drug. After research, selling and tax, about 38 cents of each sales dollar is profit.
Obesity sales grew 19% in the first half of 2026, but the whole company grew 2% because US prices fell and diabetes sales slowed. Most of the profit goes back to shareholders as dividends and buybacks.
Growth and profit
What growth costs
Growing has not made Novo more profitable: cheaper selling per sale has been eaten by rising research spending and a slightly lower gross margin, so the operating margin stayed flat. The big new cost is factories, which take a far larger slice of sales than five years ago.
Why it wins
The evidence
Patents are the protection: nobody may sell a copy of semaglutide in the US until about 2032. In a trial, people on diet and exercise alone lost 2% of their weight; on CagriSema they lost 21%.
But a patent stops copies, not a better rival drug. Lilly's tirzepatide took the US lead in 2025, and Wegovy injection sales fell 22% in the June quarter on lower prices. Medicare will pay $274 a month from 2027, and over half of users say the drugs are hard to afford.
Who could beat it
The rivals in full
Lilly is the threat. Its weekly shot outsells Novo's, its revenue grew 48% in the June quarter, its patent runs four years longer, it launched a rival pill in 2026 and plans to file an even stronger drug, retatrutide, in early 2027. Behind Lilly, generic makers such as Cipla and Sandoz are already challenging Novo's patents, and US compounding pharmacies sell unapproved copies.
Each rival
Eli Lilly tirzepatide, sold as Mounjaro and ZepboundLLY the weekly injection itself: doctors prescribe tirzepatide instead of Ozempic or Wegovy, and it now leads US prescriptions in both diabetes and obesity
Eli Lilly Foundayo (orforglipron)LLY the Wegovy pill: a daily oral GLP-1 that needs no fasting rules, launched in the June 2026 quarter
CagriSema's place as the next, stronger obesity drug, with a US submission planned for early 2027
US compounding pharmaciesprivate
branded semaglutide for cash-paying patients, with unapproved copies that Novo says continue illicitly
Cipla generic semaglutideCIPLA.NS
Ozempic at a generic price, once patents allow: Cipla has filed a paragraph IV application in the US
Sandoz generic semaglutideSDZ.SW
semaglutide in Europe, where Sandoz is challenging a dose patent in the Unified Patent Court
How big it could get
The market and who has signed
The market
The market is enormous: 890 million adults worldwide live with obesity, and one in eight American adults already takes one of these drugs. Novo treats about 4.9 million obesity patients and is paid roughly $2,700 a year for each.
So the number of patients is not what limits Novo. The price per patient is, and it is falling as Medicare and cash buyers pay far less than list.
Who runs it
Leaders, pay and the cash
Who runs it
Mike Doustdar, at Novo since 1992, became chief executive in August 2025 and cut a tenth of the staff. Karsten Knudsen has run finance since 2018 and leaves at the end of December; Luigi La Corte, now finance chief of Galderma, succeeds him. A charitable foundation controls over three quarters of the votes, so managers own almost nothing and outsiders cannot force change. Bonuses and share awards ride on sales and profit growth, none on the share price or cash, and 2025's bonus paid a quarter of the maximum.
What they did with the money
In the first half of 2026 Novo paid out DKK 41.2B, mostly as dividends, with a DKK 15B buyback running. It is also spending about DKK 55B a year on new factories, roughly as much as the cash it expects to have left over.
The last report
The latest report
Novo raised its 2026 outlook again as Wegovy pill sales passed DKK 5B
What it did to the thesis Strong quarterIt passed the test we set: sales held, the outlook rose, and the pill kept growing while injection prices fell less. It leaves open the 2027 outlook after January's US price cut.
The report
Third-quarter adjusted sales grew 4% at constant exchange rates and adjusted operating profit 27%, helped by an easy comparison with last year's restructuring costs. Novo raised its 2026 outlook to between down 2% and up 2%. The Wegovy pill sold DKK 5.4B in the quarter and US Wegovy injection sales fell 13%, a smaller fall than June's 22%.
The soft spots: profit per share still fell 12%, DKK 8.7B of non-cash write-offs hit reported profit, and the finance chief will leave at the end of December. Novo's next outlook, for 2027, is due in February.
What's happening now
The background
The shares fell 37% in the year to October 2026 while sales per share rose about 6%, so the whole fall was investors paying less for each dollar of sales. They have since risen about 8% ahead of the third-quarter report.
Two tests remain close together. The FDA is due to decide on CagriSema by the end of 2026, and the US price cut takes effect on January 1, 2027, ahead of Novo's 2027 outlook on February 3.
Where we disagree
Both sides in full
The marketNovo is a fading franchise: Lilly is winning, US prices are falling, and the shares deserve to keep sliding.
We believeThe fade is real but already in the price; Novo still gains patients, so the decline may be slower than feared.
The argument
The market might be too gloomy because the problem is price, not demand: Novo treats 4.9 million obesity patients and its new pill is the fastest US launch of this kind of drug.
The evidence against us is that analysts expect 2027 profit below 2026, and Lilly's next drug may arrive soon after CagriSema.
What it's worth
How we value it
Valued on the analysts' revenue path for three years, each later year closing 30% of the gap to 4%, on official operating profit with stock pay a cost and tax paid in full; the thesis's own evidence is the check on that path.
The three cases
Bear case$35.80
Growth runs at half the analysts' path, -9%, 2% and 4%, the margin settles a fifth lower at 31.1%, and new capital earns only the 8% rate: the downturn test.
Our value$61.61
Revenue grows -6%, 5% and 7% over three years, the analysts' path (C62), then fades toward 4%, closing 30% of the gap each year; the margin moves to 38.9%, the analysts' year-three figure after stock pay and on the filed basis (2.7% less).
Bull case$78.91
Growth runs a quarter above the analysts' path, -3%, 6% and 9%, the margin reaches 42.7%, and new capital earns 15%.
The bet
Seen as a bet
The bet is on Novo's next obesity drugs, CagriSema above all. The existing business is valued separately, at a little less than the whole company sells for today.
If CagriSema reaches millions of patients by 2029, the shares are worth only slightly more than today, because a big success is still small next to a company this large. If it fails, the existing business covers most of the price, so little is lost. It is a safe holding with little upside, not an asymmetric one.
What could go wrong
Every risk
The risks
US prices fall fasterList prices drop sharply in January 2027 and Medicare pays $274 a month; if new patients do not make up the gap, profit falls more than expected.
Lilly keeps winningLilly's drugs already lead in the US, and retatrutide could reach the market about a year after CagriSema.
The patent cliffSemaglutide's US patent ends around 2032 and generic makers have already filed, so the biggest product has a fixed end date.
One moleculeAbout three quarters of sales come from semaglutide, so one drug's price decides the company's results.
CagriSema delayed or rejectedA late or negative FDA decision would leave Novo without a new obesity drug while Lilly launches its next one.
What we still do not know
What Novo is actually paid per US patient after the 2027 list price cut and Medicare's price.
How many CagriSema patients will be new and how many will simply switch from Wegovy.
Whether the patent suit against Cipla settles on a date for a US generic before 2032.
What changes our view
Every route to a new view
Every route to a new view
→ NeutralThe share price rises to about $49.29, 80% of what we think the business is worth, so it is no longer cheap enough.
→ UnattractiveThe share price rises to about $73.93, 20% above what we think the business is worth.
→ UnattractiveNovo's 2027 outlook expects sales to fall by more than 5%.
The next test
It supports the case if2027 adjusted sales growth guided at or above -2% at constant exchange rates, with CagriSema approved or on track for a decision by mid-2027, and US Wegovy pill prescriptions still rising.
It pressures the case if2027 adjusted sales growth guided below -2% at constant exchange rates, or the CagriSema decision delayed beyond mid-2027, or US Wegovy injectable sales falling faster than the 13% of the September quarter.
We would also be wrong if
- The FDA rejects CagriSema or delays its decision beyond mid-2027.
- A US generic semaglutide launches before 2031 after a court ruling against Novo.
The verdict
Scores and how we weighed it
How we weighed it
ValuePositive
The price is about two-thirds of our value and close to the bear case.
BusinessMixed
Still hugely profitable and gaining patients, but one drug carries most sales and a rival leads both markets.
GrowthMixed
Sales fall before they recover in the value; volume has to offset steep American price cuts.
RisksNegative
Prices fall fast, the rival keeps winning, the main patent ends within years and the next drug's approval is not yet in hand.
RivalsNegative
Far cheaper than its filed rival, but that rival leads in both markets, so the gap is its own story.
The groupMixed
It sits in none of our ranked groups; it moves on its rival's trial results and American pricing rules.
Latest newsPositive
The latest report passed our test: sales held, the outlook rose and the pill kept growing.
In plain words
Patent
A legal right a government grants to an inventor. For a limited number of years nobody else may make or sell the invention. When it ends, rivals can sell cheap copies, called generics.
In plain words
Our estimate of value
We forecast how much cash the business can earn over the next ten years and beyond, then ask what that stream is worth today to an investor who wants an 8% yearly return. We do it three times: a gloomy future, an expected one and a sunny one. We call a share Attractive only when its price is at least 20% below the expected estimate, and Unattractive when it is 20% above.